PURITY SPECIFICATIONS, STORAGE, AND DISTRIBUTION FOR MEDICATIONS DEVELOPMENT CONTRACT

药物开发合同的纯度规格、储存和分发

• 批准号: 10723384
• 负责人: KATIE HAYES
• 金额: $ 7.65万
• 依托单位: RESEARCH TRIANGLE INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-07-09 至 2023-07-08
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10723384
• 关键词: Contractor; Contracts; Development; Drug Addiction; Ensure; Evaluation; Helping to End Addiction Long-term; Institutes; Medical; National Institute of Drug Abuse; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke; Neurotoxins; Pain; Pain management; Pharmaceutical Preparations; Poison; Research; Research Support; Resources; Schedule; Speed; Substance Abuse Detection; Testing; Therapeutic; United States National Institutes of Health; clinical pain; programs; repository; research and development; screening

The Division of Therapeutics and Medical Consequences (DTMC) of the National Institute on Drug Abuse (NIDA) supports research and development of new medications for the treatment of drug addiction. The objective of this contract is to provide NIDA and other NIH Institutes (NINDS and NIMH) with a a centralized confidential repository of compounds for evaluation as potential treatment agents, standards and screening agents. “This study is part of the NIH’s Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to understand the basis of pain and enhance clinical pain management.”

国家药物滥用研究所 (NIDA) 治疗和医疗后果部 (DTMC) 支持治疗毒瘾的新药物的研究和开发。此举的目的 合同的目的是为 NIDA 和其他 NIH 研究所（NINDS 和 NIMH）提供一个集中机密存储库，其中包含 用于评估作为潜在治疗剂、标准品和筛选剂的化合物。 “这项研究是 NIH 帮助结束成瘾长期 (HEAL) 计划的一部分，旨在加快科学解决方案的速度，以了解疼痛的基础并加强临床疼痛管理。”